Serum antibodies to human papillomavirus (HPV) pseudovirions correlate with natural infection for 13 genital HPV types

Journal of Clinical Virology

Volumn 56, Issue 4, 2013, Pages 336-341

  Faust, Helena ^a   Jelen, Mateja M ^b   Poljak, Mario ^b   Klavs, Irena ^c   Učakar, Veronika ^c   Dillner, Joakim ^a,d,e  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b UNIVERSITY OF LJUBLJANA   (Slovenia)

^c NATIONAL INSTITUTE OF PUBLIC HEALTH   (Slovenia)

^d KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^e KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Cervical specimens; Multiplexed HPV serology; Natural infection; Pseudovirions

Indexed keywords

VIRUS DNA;

ADULT; ARTICLE; CHILD; CONTROLLED STUDY; DNA DETERMINATION; FEMALE; GENOTYPE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 31; HUMAN PAPILLOMAVIRUS TYPE 33; HUMAN PAPILLOMAVIRUS TYPE 35; HUMAN PAPILLOMAVIRUS TYPE 39; HUMAN PAPILLOMAVIRUS TYPE 45; HUMAN PAPILLOMAVIRUS TYPE 52; HUMAN PAPILLOMAVIRUS TYPE 56; HUMAN PAPILLOMAVIRUS TYPE 58; HUMAN PAPILLOMAVIRUS TYPE 59; HUMAN PAPILLOMAVIRUS TYPE 6; HUMAN PAPILLOMAVIRUS TYPE 68; HUMAN PAPILLOMAVIRUS TYPE 73; HUMAN TISSUE; JC VIRUS; MAJOR CLINICAL STUDY; MERKEL CELL POLYOMAVIRUS; PAPILLOMAVIRUS INFECTION; PRESCHOOL CHILD; PRIORITY JOURNAL; PSEUDOVIRION; SCHOOL CHILD; SCREENING TEST; SEROLOGY; SEROPREVALENCE; SLOVENIA; UTERINE CERVIX CYTOLOGY; VIRION; WART VIRUS;

ADULT; ALPHAPAPILLOMAVIRUS; ANTIGENS, VIRAL; CASE-CONTROL STUDIES; CERVIX UTERI; COINFECTION; DNA, VIRAL; EARLY DETECTION OF CANCER; FEMALE; HUMANS; MIDDLE AGED; ODDS RATIO; PAPILLOMAVIRUS INFECTIONS; SENSITIVITY AND SPECIFICITY; SEROLOGIC TESTS; SLOVENIA; UTERINE CERVICAL NEOPLASMS; VAGINAL SMEARS; YOUNG ADULT;

EID: 84875087062     PISSN: 13866532     EISSN: 18735967     Source Type: Journal    
DOI: 10.1016/j.jcv.2012.12.004     Document Type: Article

References (29)

1. Ferlay J., Shin H.R., Bray F., Forman D., Mathers C., Parkin D.M. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2008, 127(12):2893-2917. [Epub 26.02.11].
2. Parkin D.M. The global health burden of infection-associated cancers in the year 2002. Int J Cancer 2006, 118(12):3030-3044. [Epub 13.01.06].
3. Harper D.M., Franco E.L., Wheeler C., Ferris D.G., Jenkins D., Schuind A., et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 2004, 364(9447):1757-1765. [Epub 16.11.04].
4. Villa L.L., Costa R.L., Petta C.A., Andrade R.P., Paavonen J., Iversen O.E., et al. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br J Cancer 2006, 95(11):1459-1466. [Epub 23.11.06].
5. Stanley M. Potential mechanisms for HPV vaccine-induced long-term protection. Gynecol Oncol 2010, 118(Suppl. 1):S2-S7. [Epub 04.06.10].
6. Gersch E.D., Gissmann L., Garcea R.L. New approaches to prophylactic human papillomavirus vaccines for cervical cancer prevention. Antivir Ther 2012, 17(3):425-434. [Epub 02.02.12].
7. Molano M., Van den Brule A., Plummer M., Weiderpass E., Posso H., Arslan A., et al. Determinants of clearance of human papillomavirus infections in Colombian women with normal cytology: a population-based, 5-year follow-up study. Am J Epidemiol 2003, 158(5):486-494. [Epub 26.08.03].
8. Carter J.J., Koutsky L.A., Hughes J.P., Lee S.K., Kuypers J., Kiviat N., et al. Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection. J Infect Dis 2000, 181(6):1911-1919. [Epub 06.06.00].
9. Ho G.Y., Studentsov Y.Y., Bierman R., Burk R.D. Natural history of human papillomavirus type 16 virus-like particle antibodies in young women. Cancer Epidemiol Biomarkers Prev 2004, 13(1):110-116. [Epub 28.01.04].
10. Dillner J. The serological response to papillomaviruses. Semin Cancer Biol 1999, 9(6):423-430. [Epub 14.03.00].
11. Tiggelaar S.M., Lin M.J., Viscidi R.P., Ji J., Smith J.S. Age-specific human papillomavirus antibody and deoxyribonucleic acid prevalence: a global review. J Adolesc Health 2012, 50(2):110-131. [Epub 24.01.12].
12. Combita A.L., Bravo M.M., Touze A., Orozco O., Coursaget P. Serologic response to human oncogenic papillomavirus types 16, 18, 31, 33, 39, 58 and 59 virus-like particles in colombian women with invasive cervical cancer. Int J Cancer 2002, 97(6):796-803. [Epub 22.02.02].
13. Wang S.S., Schiffman M., Shields T.S., Herrero R., Hildesheim A., Bratti M.C., et al. Seroprevalence of human papillomavirus-16, -18, -31, and -45 in a population-based cohort of 10,000 women in Costa Rica. Br J Cancer 2003, 89(7):1248-1254. [Epub 02.10.03].
14. Faust H., Knekt P., Forslund O., Dillner J. Validation of multiplexed human papillomavirus serology using pseudovirions bound to heparin-coated beads. J Gen Virol 2010, 91(Pt 7):1840-1848. [Epub 26.02.10].
15. Poljak M., Ostrbenk A., Seme K., Ucakar V., Hillemanns P., Bokal E.V., et al. Comparison of clinical and analytical performance of the abbott realtime high risk HPV test to the performance of hybrid capture 2 in population-based cervical cancer screening. J Clin Microbiol 2011, 49(5):1721-1729. [Epub 25.03.11].
16. Ucakar V., Poljak M., Klavs I. Pre-vaccination prevalence and distribution of high-risk human papillomavirus (HPV) types in Slovenian women: a cervical cancer screening based study. Vaccine 2012, 30(2):116-120. [Epub 15.11.11].
17. af Geijersstam V., Eklund C., Wang Z., Sapp M., Schiller J.T., Dillner J., et al. A survey of seroprevalence of human papillomavirus types 16, 18 and 33 among children. Int J Cancer 1999, 80(4):489-493. [Epub 06.02.99].
18. Kjellberg L., Wang Z., Wiklund F., Edlund K., Angstrom T., Lenner P., et al. Sexual behaviour and papillomavirus exposure in cervical intraepithelial neoplasia: a population-based case-control study. J Gen Virol 1999, 80(Pt 2):391-398. [Epub 12.03.99].
19. Buck C.B., Pastrana D.V., Lowy D.R., Schiller J.T. Efficient intracellular assembly of papillomaviral vectors. J Virol 2004, 78(2):751-757. [Epub 25.12.03].
20. Eklund C., Unger E.R., Nardelli-Haefliger D., Zhou T., Dillner J. International collaborative proficiency study of human papillomavirus type 16 serology. Vaccine 2012, 30(2):294-299. [Epub 15.11.11].
21. Antonsson A., Karanfilovska S., Lindqvist P.G., Hansson B.G. General acquisition of human papillomavirus infections of skin occurs in early infancy. J Clin Microbiol 2003, 41(6):2509-2514. [Epub 07.06.03].
22. Michael K.M., Waterboer T., Sehr P., Rother A., Reidel U., Boeing H., et al. Seroprevalence of 34 human papillomavirus types in the German general population. PLoS Pathog 2008, 4(6):e1000091. [Epub 21.06.08].
23. Chen T., Hedman L., Mattila P.S., Jartti T., Ruuskanen O., Soderlund-Venermo M., et al. Serological evidence of Merkel cell polyomavirus primary infections in childhood. J Clin Virol 2011, 50(2):125-129. [Epub 26.11.10].
24. Faust H., Pastrana D.V., Buck C.B., Dillner J., Ekstrom J. Antibodies to merkel cell polyomavirus correlate to presence of viral DNA in the skin. J Infect Dis 2011, 203(8):1096-1100. [Epub 01.04.11].
25. Schwarz T.F., Spaczynski M., Schneider A., Wysocki J., Galaj A., Perona P., et al. Immunogenicity and tolerability of an HPV-16/18 AS04-adjuvanted prophylactic cervical cancer vaccine in women aged 15-55 years. Vaccine 2009, 27(4):581-587. [Epub 22.11.08].
26. Eklund C., Forslund O., Wallin K.L., Zhou T., Dillner J. The 2010 global proficiency study of human papillomavirus genotyping in vaccinology. J Clin Microbiol 2012, [Epub 27.04.12].
27. Brown D.R., Kjaer S.K., Sigurdsson K., Iversen O.E., Hernandez-Avila M., Wheeler C.M., et al. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years. J Infect Dis 2009, 199(7):926-935. [Epub 25.02.09].
28. Smith J.F., Brownlow M., Brown M., Kowalski R., Esser M.T., Ruiz W., et al. Antibodies from women immunized with gardasil cross-neutralize HPV 45 pseudovirions. Hum Vaccin 2007, 3(4):109-115. [Epub 06.07.07].
29. Wheeler C.M., Castellsague X., Garland S.M., Szarewski A., Paavonen J., Naud P., et al. Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol 2011, 13(1):100-110. [Epub 15.11.11].